Ischemic Colitis and Mesenteric Ischemia

• Acute arterial occlusion and reduced oxygen delivery: The mesenteric circulation comprises the superior mesenteric artery (SMA), inferior mesenteric artery (IMA), and celiac axis, which supply distinct intestinal segments with remarkable functional redundancy through collateral networks (marginal arteries of Drummond, arc of Riolan). When acute occlusion occurs—typically via thromboembolism from cardiac arrhythmias, atherosclerotic plaques, or aortic dissection—collateral flow cannot acutely compensate, resulting in immediate reduction in oxygen delivery (DO₂). The mucosa is most vulnerable because it exists at the "watershed" of intestinal perfusion; the submucosa follows, and full-thickness involvement develops within 6–8 hours. Ischemic injury triggers anaerobic metabolism within minutes, leading to lactate accumulation, depletion of adenosine triphosphate (ATP), and loss of cellular membrane integrity. This cellular dysfunction manifests as increased intestinal permeability, bacterial translocation, and release of cytochrome c, activating apoptotic pathways that extend injury beyond initially hypoxic tissue.

• Low-flow states and non-occlusive mesenteric ischemia (NOMI): Approximately 25–50% of acute mesenteric ischemia cases result from inadequate mesenteric perfusion without anatomic occlusion, termed NOMI. This occurs in states of systemic hypoperfusion (cardiogenic shock, septic shock, severe dehydration) when splanchnic vasoconstriction occurs as part of the baroreceptor-mediated sympathetic response to maintain perfusion to vital organs (brain, heart). Catecholamines cause preferential vasoconstriction of mesenteric arterioles through α₁-adrenergic stimulation, which is functionally appropriate systemically but creates a lethal situation in the gut. Paradoxically, this vasoconstriction persists even after restoration of systemic perfusion, leading to continued intestinal ischemia—a phenomenon reversible with vasodilators like papaverine but often irreversible once transmural necrosis develops. The gradient between arterial and venous oxygen content progressens progressively, exacerbated by increased local oxygen extraction from the hypoxic tissue's metabolic desperation.

• Venous thrombosis and mucosal congestion: Mesenteric venous thrombosis (MVT), accounting for 5–15% of acute mesenteric ischemia, creates a unique pathophysiology whereby venous obstruction leads to increased hydrostatic pressure in the capillary bed, venous congestion, and secondary mucosal edema. Unlike arterial insufficiency, the initial phase of MVT may allow continued arterial inflow with impaired drainage, creating a "congested but perfused" state. However, persistent venous obstruction elevates intramural pressure beyond capillary hydrostatic pressure, causing collapse of mucosal arterioles (transmural pressure gradient reversal) and paradoxical transition to ischemia despite patent feeding arteries. This explains why MVT can present more insidiously—early imaging may show only venous congestion, but without anticoagulation and collateral development, progression to arterial insufficiency and transmural necrosis occurs within days to weeks.

• Reperfusion injury and inflammatory cascade: Even when vascular flow is restored (via revascularization or spontaneous lysis), restoration of oxygen delivery triggers the reperfusion injury cascade. Ischemic tissue becomes depleted of the electron acceptor nicotinamide adenine dinucleotide (NAD⁺) and accumulates hypoxanthine and xanthine. Upon reperfusion, molecular oxygen immediately reoxidizes xanthine dehydrogenase to xanthine oxidase, which catalyzes conversion of hypoxanthine to xanthate radicals and uric acid, generating destructive reactive oxygen species (ROS) including superoxide and hydroxyl radicals. These ROS overwhelm endogenous antioxidant defenses (superoxide dismutase, catalase, glutathione peroxidase) and cause lipid peroxidation of cell membranes, further propagating cell death. Simultaneously, reperfusion triggers toll-like receptor (TLR) signaling and activation of the nuclear factor kappa B (NF-κB) pathway, amplifying the inflammatory response with release of tumor necrosis factor-alpha (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6). This excessive inflammatory state explains the paradox of worsening clinical status immediately after revascularization and justifies the use of anti-inflammatory measures (fluid resuscitation, broad-spectrum antibiotics) perioperatively.

• Functional impairment of the intestinal barrier: Independently of cell death, ischemia rapidly disrupts the tight junction complex (occludin, claudins, zonula occludens-1 proteins) that normally maintain a selectively permeable epithelial barrier. Within 15–30 minutes of ischemia onset, zonula occludens-1 protein is internalized from the apical tight junction, increasing paracellular permeability. This allows translocation of lipopolysaccharide (LPS) and viable bacteria across the epithelium, triggering a profound LPS-mediated inflammatory response via CD14 and TLR4 signaling. The mucus layer, normally produced by goblet cells, is also impaired, losing its antimicrobial peptide-rich barrier function. This combination explains why intestinal ischemia rapidly progresses to systemic signs (fever, tachycardia, leukocytosis) and later sepsis and multiple organ dysfunction syndrome (MODS) even with small areas of initial necrosis.

• Chronic ischemic pathophysiology in ischemic colitis: Chronic ischemic colitis typically results from less severe reduction in IMA flow, often secondary to IMA stenosis from atherosclerosis, external compression, or functional shunting of blood away from distal colonic branches. Unlike the acute fulminant presentation of arterial occlusion, chronic ischemia triggers angiogenesis through hypoxia-inducible factor-1 alpha (HIF-1α) signaling and upregulation of vascular endothelial growth factor (VEGF), allowing development of collateral circulation. However, episodic reductions in flow (from dietary triggers, medications, or systemic dehydration) can cause intermittent mucosal injury, leading to repeated cycles of ulceration and healing. The chronically ischemic mucosa remains thin, friable, and prone to bleeding, with fibrosis developing in the submucosa and muscularis propria after repeated insults.

• Acute arterial thromboembolism (accounts for ~50% of acute mesenteric ischemia): Cardiac sources of embolism represent the most common cause in acute mesenteric ischemia. Atrial fibrillation is responsible for the majority of emboli (approximately 50% of all embolic events), with other cardiac sources including left ventricular thrombus post-myocardial infarction, dilated cardiomyopathy, endocarditis, mechanical heart valves, and cardiac tumors (atrial myxoma). The SMA is the most common site of lodgement (60–70% of emboli) because of its larger diameter and more anterior take-off from the aorta compared to the celiac axis and IMA. Thromboembolism within the SMA typically lodges at the bifurcation of the first jejunal branch (approximately 6–10 cm from the SMA origin), creating a "saddle embolus." Secondary arterial thrombosis occurs when atherosclerotic plaques at the ostium of mesenteric vessels rupture, typically in patients with established atherosclerotic disease and often preceded by a period of low-flow states.

• Acute arterial thrombosis from atherosclerotic disease: Atherosclerotic narrowing of mesenteric arteries is extremely common (25–60% of autopsy series show significant stenosis) but usually remains asymptomatic because of rich collateral circulation. Acute thrombosis superimposed on chronic stenosis typically occurs when systemic hypotension or local thrombotic events reduce collateral flow below the threshold necessary for bowel viability. Patients often have a history of smoking, diabetes, hypertension, hyperlipidemia, and established peripheral or coronary arterial disease. Risk of progression is higher with high-grade stenosis (>70%) combined with poor collateral development.

• Mesenteric venous thrombosis (5–15% of acute mesenteric ischemia): Primary MVT occurs in hypercoagulable states including myeloproliferative disorders (polycythemia vera, essential thrombocythemia, primary myelofibrosis—accounting for ~40% of MVT cases), malignancy (particularly hepatocellular carcinoma and pancreatic cancer), inherited thrombophilias (Factor V Leiden, prothrombin G20210A mutation, protein C/S deficiency, antithrombin deficiency), antiphospholipid syndrome, and oral contraceptive use. Secondary MVT results from inflammation or infection of adjacent organs (diverticulitis, appendicitis, pancreatitis, inflammatory bowel disease), trauma, surgery, or portal hypertension with splenomegaly and portal vein thrombosis.

• Non-occlusive mesenteric ischemia (25–50% of acute mesenteric ischemia): NOMI occurs in states of systemic hypoperfusion and is a major cause of mesenteric ischemia in hospitalized patients. Predisposing conditions include cardiogenic shock (acute myocardial infarction, acute decompensated heart failure), septic shock, severe dehydration or hemorrhagic shock, and prolonged hypotension from any cause. Medications that induce splanchnic vasoconstriction increase NOMI risk, particularly high-dose vasopressors (epinephrine, phenylephrine) used in shock states and to a lesser extent, certain diuretics and NSAIDs. Historically, cocaine use was a recognized cause of NOMI, though currently less common. NOMI has the worst prognosis of all acute mesenteric ischemia types because the diagnosis is often delayed (no obvious occlusion on angiography) and the underlying hypoperfusion state may be multifactorial and difficult to reverse.

• Ischemic colitis risk factors: Low-flow states account for the majority of ischemic colitis cases—systemic hypotension from any cause (major surgery, trauma, hemorrhage, myocardial infarction, sepsis, dehydration). Colonoscopy itself carries a small risk, particularly with aggressive insufflation causing increased intraluminal pressure and splanchnic vasoconstriction. Medications that reduce mesenteric flow include NSAIDs (by inhibiting prostaglandin-mediated vasodilation), ACE inhibitors and angiotensin receptor blockers (in susceptible patients with renal artery stenosis or volume depletion), antipsychotics causing orthostatic hypotension, and stimulant laxatives causing rapid volume shifts. Structural colonic obstruction (carcinoma, stricture, volvulus) causes increased intraluminal pressure upstream and, if the ileocecal valve is competent, increases right colon pressure and ischemia risk ("closed loop" obstruction). Vasculitis from systemic lupus erythematosus, polyarteritis nodosa, or thrombotic thrombocytopenic purpura can cause ischemic colitis. Thrombophilic states including antiphospholipid syndrome, hypercoagulable malignancy, or homocysteinemia increase colitis risk but are less commonly identified than in acute arterial mesenteric ischemia.

• Chronic mesenteric ischemia: Chronic ischemic colitis is rare but classically results from IMA stenosis or occlusion from atherosclerotic disease, particularly when collaterals are inadequate. Risk factors mirror those for systemic atherosclerosis (age, smoking, diabetes, hypertension). Occasional cases result from external compression of the IMA (aortic aneurysm, malignancy compressing the mesenteric root) or functional "steal" phenomena where superior or inferior mesenteric branches preferentially perfuse other organs.

• Acute severe abdominal pain disproportionate to physical exam findings: This is the cardinal symptom of acute mesenteric ischemia and represents one of the most important clinical clues. The pain is typically sudden in onset (especially with embolic disease), severe (often 8–10/10 intensity), and described as cramp-like or colicky initially, then becomes steady and diffuse. The pain is visceral rather than somatic, so it is often periumbilical or epigastric in SMA distribution or left lower quadrant in IMA distribution, though it frequently becomes diffuse as transmural ischemia develops. Critically, physical exam findings lag behind the degree of tissue damage—bowel tenderness, guarding, and rebound rigidity (signifying peritonitis) indicate advanced disease with likely transmural necrosis and perforation, whereas early ischemia (first 6 hours) may present with only mild or no abdominal tenderness. This dissociation ("pain out of proportion to exam findings") is pathognomonic and should immediately raise suspicion for mesenteric ischemia. The mechanism reflects that visceral ischemia activates nociceptors while intact peritoneum and visceral pleura remain uninvolved until necrosis extends transmurally.

• Bloody diarrhea or hematochezia (later finding in acute mesenteric ischemia): Though classically described, bloody stools occur relatively late in acute mesenteric ischemia (after 6–12 hours) when mucosal sloughing and ulceration have developed. Hematochezia indicates colonic involvement or distal small bowel ischemia; melena is less common and suggests proximal small bowel ischemia. The absence of bloody diarrhea early does not exclude mesenteric ischemia. In contrast, bloody diarrhea may be an earlier finding in ischemic colitis, particularly in less fulminant presentations.

• Nausea and vomiting: Early vomiting (within first hours) reflects visceral sensory input and splanchnic autonomic reflexes rather than obstruction. Vomiting may help the patient by reducing intra-abdominal pain momentarily but provides no protective mechanism for the ischemic bowel. Persistent or worsening vomiting accompanied by abdominal distension indicates progression to ileus or early perforation with peritonitis.

• Diarrhea (often preceding bloody stools): Watery diarrhea from ischemia reflects impaired intestinal water absorption and secretion from loss of epithelial integrity, increased mucosal permeability, and inflammatory mediators (prostaglandins, serotonin) acting on intestinal smooth muscle. In ischemic colitis, diarrhea is often an early symptom and may occur in isolation if the insult is mild and self-limited.

• Systemic signs of shock and sepsis: Progressive ischemia and bacterial translocation trigger systemic inflammatory response syndrome (SIRS) with fever, tachycardia (often pronounced, >120 bpm), tachypnea, and leukocytosis (often 15,000–20,000 cells/μL). Hypotension appears late and indicates advanced disease with septic or hemorrhagic shock. These signs reflect bacteremia from translocation of gram-negative organisms (especially E. coli, Klebsiella, anaerobes) and LPS-mediated endotoxemia activating the complement cascade, tissue factor pathway, and innate immune cells.

• Abdominal distension and absence of bowel sounds: Ileus develops as ischemia impairs intestinal muscle function and triggers neurogenic suppression of peristalsis. Progressive distension indicates either accumulating intraluminal contents or third-spacing of fluid into the peritoneal cavity from increased capillary permeability and transmural inflammation. Absence of bow

Initial evaluation (do not let labs delay imaging)

• Laboratory studies: leukocytosis, hemoconcentration, and an anion-gap metabolic acidosis with elevated lactate are typical but late — normal lactate early does not exclude ischemia, because portal clearance and hepatic extraction buffer it until necrosis is extensive. Elevated amylase, LDH, and D-dimer are sensitive but nonspecific; a normal D-dimer makes acute mesenteric ischemia less likely.
• Plain radiography: obtained mainly to exclude perforation or obstruction. Thumbprinting (submucosal edema/hemorrhage) is classic but insensitive; pneumatosis intestinalis and portal venous gas are late, ominous signs.

Confirmatory imaging

• Biphasic CT angiography of the abdomen/pelvis is the test of choice for suspected acute mesenteric ischemia (ACR Appropriateness Criteria; supported by AGA and WSES guidance). Use IV contrast with arterial and portal venous phases and no positive oral contrast, which obscures mucosal enhancement. Findings: abrupt arterial cutoff or filling defect (embolus classically distal to the first jejunal branch of the SMA), venous filling defect in MVT, bowel wall thinning or absent enhancement (arterial), wall thickening with mesenteric fat stranding and ascites (venous), pneumatosis, portal gas.
• Catheter mesenteric angiography remains the reference standard and is preferred when NOMI is suspected — it shows diffuse narrowing and "string-of-sausage" spasm without occlusion, and permits intra-arterial vasodilator therapy.

Ischemic colitis

• CT first, colonoscopy to confirm: the ACG 2015 colon ischemia guideline recommends early CT followed by colonoscopy (generally within about 48 hours) with minimal insufflation, unless gangrene or peritonitis is suspected. Segmental involvement of a watershed zone (Griffiths point, splenic flexure; Sudeck point, rectosigmoid) with rectal sparing and the single-stripe sign are characteristic; biopsy may show ghost cells and hyalinized lamina propria.
• Chronic mesenteric ischemia: mesenteric duplex ultrasound screens (elevated peak systolic velocities in the celiac axis/SMA), with CTA confirming multivessel stenosis (Society for Vascular Surgery 2020 guideline). No validated clinical scoring system is in routine use.

Immediate stabilization (all types)

• Resuscitation: bowel rest, nasogastric decompression, and aggressive isotonic crystalloid — third-spacing losses are large. Correct acidosis and electrolytes; surgical consultation should be simultaneous, not sequential.
• Broad-spectrum antibiotics: cover gram-negatives and anaerobes for bacterial translocation (e.g., piperacillin-tazobactam, or a carbapenem in critically ill patients), consistent with WSES and SIS intra-abdominal infection guidance.
• Anticoagulation: unfractionated heparin for arterial occlusive disease and mesenteric venous thrombosis once perforation/bleeding is excluded.
• Contraindicated/avoid: alpha-agonist vasopressors and digoxin worsen splanchnic vasoconstriction; if pressors are unavoidable, use the lowest effective dose and prefer agents with less mesenteric vasoconstriction. Barium studies are contraindicated (perforation risk, obscures angiography). Colonoscopy is contraindicated with peritonitis or suspected gangrene.

Definitive therapy by mechanism

• Arterial embolism: emergent revascularization — open SMA embolectomy or endovascular aspiration/thrombolysis — plus laparotomy to resect frankly necrotic bowel. Second-look laparotomy at 24–48 hours is standard when viability is uncertain.
• Arterial thrombosis on atherosclerotic plaque: endovascular stenting or bypass/endarterectomy.
• NOMI: reverse the low-flow state (treat cardiogenic/septic shock, wean vasoconstrictors) and give intra-arterial vasodilator therapy — papaverine infusion via the SMA catheter.
• Mesenteric venous thrombosis: anticoagulation alone is first-line (heparin bridged to warfarin or a DOAC); surgery only for peritonitis or infarction. Evaluate for myeloproliferative neoplasm and thrombophilia.
• Ischemic colitis: per the ACG 2015 colon ischemia guideline, most non-gangrenous cases are managed supportively with fluids, bowel rest, and withdrawal of vasoconstrictive/offending drugs; antibiotics are reserved for moderate-to-severe disease. Anticoagulation and angiography are not routine. Surgery (segmental colectomy) is indicated for gangrene, perforation, fulminant pancolitis, refractory hemorrhage, or a symptomatic post-ischemic stricture.
• Chronic mesenteric ischemia: endovascular revascularization with stenting is first-line in symptomatic disease (Society for Vascular Surgery), with open bypass reserved for anatomy unsuitable for stenting; smoking cessation and statin therapy address the underlying atherosclerosis.

Emergencies

• Transmural infarction with perforation: full-thickness necrosis develops within roughly 6–12 hours of complete arterial occlusion. Signaled by peritonitis (rigidity, rebound), free intraperitoneal air on imaging, and hemodynamic collapse. Requires immediate laparotomy.
• Septic shock and MODS: loss of tight-junction integrity permits translocation of enteric gram-negatives and endotoxin; heralded by fever, worsening lactate, refractory hypotension, and rising vasopressor requirement.
• Pneumatosis intestinalis with portal venous gas: gas dissects into the bowel wall and mesenteric veins from necrotic mucosa — a marker of established infarction and high mortality.
• Gangrenous/fulminant ischemic colitis and toxic megacolon: right-sided colonic involvement (SMA territory) carries the worst prognosis; progressive distension with systemic toxicity is an operative indication.
• Abdominal compartment syndrome: massive bowel edema plus large-volume resuscitation raises intra-abdominal pressure, producing oliguria, high airway pressures, and falling cardiac output; decompressive laparotomy is definitive.

Post-ischemic and treatment-related

• Reperfusion injury: xanthine oxidase–derived reactive oxygen species and cytokine release cause paradoxical clinical deterioration in the hours after revascularization.
• Colonic stricture: submucosal fibrosis weeks to months after a segmental insult; presents as obstructive symptoms or a persistent segmental narrowing on follow-up imaging.
• Chronic segmental ischemic colitis: persistent bloody diarrhea, protein-losing enteropathy, or recurrent sepsis; may mimic inflammatory bowel disease and requires resection.
• Short bowel syndrome: after extensive small-bowel resection, producing malabsorption, diarrhea, and long-term parenteral nutrition dependence.
• Anticoagulation-related hemorrhage, particularly into already ulcerated ischemic mucosa.
• Contrast-associated acute kidney injury and access-site complications (dissection, distal embolization) from CTA/endovascular therapy.
• Recurrent thrombosis or stent restenosis after revascularization, presenting as recurrent postprandial pain and weight loss.

• Pain out of proportion to examination in an elderly patient with atrial fibrillation who is not anticoagulated = acute SMA embolism until proven otherwise. The single best next step is biphasic CT angiography (IV contrast, no positive oral contrast), not a lactate level and not plain films.
• A normal lactate does not exclude acute mesenteric ischemia. Lactate and leukocytosis rise late; waiting for them is the classic exam trap that leads to a dead-bowel vignette.
• Watershed anatomy is the tested association: the splenic flexure (Griffiths point) and rectosigmoid junction (Sudeck point) are the vulnerable zones in ischemic colitis. The rectum is spared because of dual supply from the middle/inferior rectal arteries (internal iliac) — rectal involvement should push you toward infectious or inflammatory colitis instead.
• Ischemic colitis ≠ acute mesenteric ischemia. Ischemic colitis is typically hemodynamic/nonocclusive, presents with mild left-sided pain and bloody diarrhea, and per the ACG 2015 guideline is managed supportively with colonoscopy for confirmation — angiography, anticoagulation, and emergent surgery are the distractors.
• Postprandial abdominal pain + food fear + weight loss in a vasculopath = chronic mesenteric ischemia (intestinal angina); symptoms usually require multivessel stenosis given the collateral network. Endovascular stenting is first-line (Society for Vascular Surgery).
• Mesenteric venous thrombosis is the young patient with subacute, days-long pain and a hypercoagulable state (myeloproliferative neoplasm, OCPs, Factor V Leiden). Treatment is systemic anticoagulation, not embolectomy.
• Radiographic buzzwords: thumbprinting on plain film/CT (submucosal edema); pneumatosis intestinalis and portal venous gas indicate infarction.
• Things not to do: barium enema (perforation risk), colonoscopy in a patient with peritoneal signs, and alpha-agonist vasopressors or digoxin, all of which worsen splanchnic vasoconstriction. When bowel viability is uncertain intraoperatively, plan a second-look laparotomy.